Helus Pharma Inc. income statement

In fiscal 2022, Helus Pharma Inc. reported revenue of $0, down 100.0% on the year before and net income of −$54.0m, or −$0.32 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Helus Pharma Inc.: income statement, annual
Fiscal year	2021Mar 2021	2022Mar 2022
Revenue	1	0
Gross profit	0	0
Net income	−24	−54
Diluted EPS	−$0.24	−$0.32
Diluted shares (average)	100m	167m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Helus Pharma Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Helus Pharma Inc.